JP2005516904A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516904A5
JP2005516904A5 JP2003546899A JP2003546899A JP2005516904A5 JP 2005516904 A5 JP2005516904 A5 JP 2005516904A5 JP 2003546899 A JP2003546899 A JP 2003546899A JP 2003546899 A JP2003546899 A JP 2003546899A JP 2005516904 A5 JP2005516904 A5 JP 2005516904A5
Authority
JP
Japan
Prior art keywords
levonorgestrel
active ingredient
formulation
dose
additives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003546899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516904A (ja
Filing date
Publication date
Priority claimed from HU0105173A external-priority patent/HU227198B1/hu
Application filed filed Critical
Publication of JP2005516904A publication Critical patent/JP2005516904A/ja
Publication of JP2005516904A5 publication Critical patent/JP2005516904A5/ja
Withdrawn legal-status Critical Current

Links

JP2003546899A 2001-11-27 2002-11-26 緊急避妊のための薬学的組成物およびその用量処方 Withdrawn JP2005516904A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0105173A HU227198B1 (en) 2001-11-27 2001-11-27 Pharmaceutical composition for emergency contraception containing levonorgestrel
PCT/HU2002/000129 WO2003045397A1 (en) 2001-11-27 2002-11-26 Dosage regimen and pharmaceutical composition for emergency contraception

Publications (2)

Publication Number Publication Date
JP2005516904A JP2005516904A (ja) 2005-06-09
JP2005516904A5 true JP2005516904A5 (enExample) 2006-01-05

Family

ID=89998939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003546899A Withdrawn JP2005516904A (ja) 2001-11-27 2002-11-26 緊急避妊のための薬学的組成物およびその用量処方

Country Status (33)

Country Link
US (1) US20050288264A2 (enExample)
EP (1) EP1448207B1 (enExample)
JP (1) JP2005516904A (enExample)
KR (1) KR100908161B1 (enExample)
CN (1) CN1551774A (enExample)
AP (1) AP1849A (enExample)
AT (1) ATE293978T1 (enExample)
AU (1) AU2002347401A1 (enExample)
BR (1) BR0210595A (enExample)
CA (1) CA2450359C (enExample)
DE (1) DE60203929T2 (enExample)
DK (1) DK1448207T3 (enExample)
EA (1) EA006545B1 (enExample)
EC (1) ECSP045171A (enExample)
ES (1) ES2239727T3 (enExample)
GE (1) GEP20063882B (enExample)
HR (1) HRP20040584B1 (enExample)
HU (1) HU227198B1 (enExample)
IL (1) IL159394A0 (enExample)
IS (1) IS2691B (enExample)
MA (1) MA27076A1 (enExample)
MX (1) MXPA04005104A (enExample)
NO (1) NO333984B1 (enExample)
NZ (1) NZ530056A (enExample)
OA (1) OA12730A (enExample)
PL (1) PL206010B1 (enExample)
PT (1) PT1448207E (enExample)
RS (1) RS50768B (enExample)
SI (1) SI1448207T1 (enExample)
TN (1) TNSN04048A1 (enExample)
UA (1) UA79942C2 (enExample)
WO (1) WO2003045397A1 (enExample)
ZA (1) ZA200404114B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674776A1 (en) * 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
US9180131B2 (en) 2008-12-12 2015-11-10 Laboratoire Hra Pharma Method for contraception
PT2419108T (pt) 2009-04-14 2016-11-07 Hra Pharma Lab Método para contracepção quando necessária
NZ597239A (en) 2009-06-23 2013-07-26 Bayer Pharma AG Pharmaceutical composition for emergency contraception
CN101732324B (zh) * 2009-12-31 2011-12-07 广州朗圣药业有限公司 一种含有左炔诺孕酮的紧急避孕药物组合物及其制备方法
JP6425540B2 (ja) 2011-06-01 2018-11-21 エステトラ エス.ペ.エール.エル. エステトロール中間体を製造するための方法
EP2714712B1 (en) 2011-06-01 2016-08-24 Estetra S.P.R.L. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
SMT201700310T1 (it) * 2011-08-11 2017-07-18 Estetra Sprl Uso dell'esterolo come contraccettivo di emergenza
AP2015008437A0 (en) 2012-11-22 2015-05-31 Bayer Pharma AG Use and application regimen of a pharmaceutical composition containing levonorgestrel and a cox inhibitor for on-demand contraception
WO2014187744A1 (de) 2013-05-23 2014-11-27 Bayer Pharma Aktiengesellschaft Pharmazeutische zusammensetzung und deren verwendung sowie anwendungsregime dieser pharmazeutischen zusammensetzung zur bedarfsweisen („on-demand") kontrazeption
CN103877058A (zh) * 2014-03-26 2014-06-25 邵娜 一种左炔诺孕酮片及其制备工艺
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
NZ737948A (en) 2015-06-18 2023-03-31 Estetra Sprl Orodispersible dosage unit containing an estetrol component
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
KR102662025B1 (ko) 2015-06-18 2024-05-02 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CN110917154A (zh) * 2019-12-12 2020-03-27 上海信谊天平药业有限公司 一种左炔诺孕酮片的制备方法
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
US20230338355A1 (en) * 2020-07-30 2023-10-26 Acer Therapeutics Inc. Nk antagonists for contraception
CN119523923A (zh) * 2024-11-21 2025-02-28 华中药业股份有限公司 一种左炔诺孕酮片及其制备方法

Similar Documents

Publication Publication Date Title
JP2005516904A5 (enExample)
AP1849A (en) Dosage regimen and pharmaceutical composition for emergency contraception
KR101612197B1 (ko) 부프로피온 염산염을 함유하는 안정화된 정제 및 이의 제조방법
JP2005515966A5 (enExample)
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
HU197840B (en) Process for producing synergic pharmaceutical compositions comprising amantadin and selegilin
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
JPH0635382B2 (ja) 抗不安薬としてのフルオキセチンの使用法
JP2005015479A (ja) 局所麻酔薬を含有する口中用または咽頭部用製剤
ES2383433T3 (es) Formulación farmacéutica de apomorfina para administración bucal
EA018589B1 (ru) Применение композиции, содержащей формотерол и дипропионат беклометазона, для предотвращения и/или лечения обострения астмы
JP2005531612A (ja) ネフォパムの製剤および痛みの治療におけるその使用
JPH04210924A (ja) カルシトニンの経口投与用の製薬組成物及び投薬形態
JP4752987B2 (ja) 外用剤組成物
JP2019532112A5 (ja) 結節性痒疹を治療するための抗掻痒剤
ES2241777T3 (es) Composiciones farmaceuticas que contienen terbinafina.
JP2019509309A5 (enExample)
HRP20251043T1 (hr) Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća
ITMI20080798A1 (it) Composizione a rilascio modificato a base di doxofillina
CN1372468A (zh) 羟乙磷酸二钠口服制剂
KR100762598B1 (ko) 항혈전성 화합물을 포함하는 구강분산성 약제 조성물
EP3297612B1 (en) Pharmaceutical composition comprising atomoxetine and method for the preparation thereof
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins